204 related articles for article (PubMed ID: 21724375)
1. Resistance of the Burkholderia cepacia complex to fosmidomycin and fosmidomycin derivatives.
Messiaen AS; Verbrugghen T; Declerck C; Ortmann R; Schlitzer M; Nelis H; Van Calenbergh S; Coenye T
Int J Antimicrob Agents; 2011 Sep; 38(3):261-4. PubMed ID: 21724375
[TBL] [Abstract][Full Text] [Related]
2. Fosmidomycin decreases membrane hopanoids and potentiates the effects of colistin on Burkholderia multivorans clinical isolates.
Malott RJ; Wu CH; Lee TD; Hird TJ; Dalleska NF; Zlosnik JE; Newman DK; Speert DP
Antimicrob Agents Chemother; 2014 Sep; 58(9):5211-9. PubMed ID: 24957830
[TBL] [Abstract][Full Text] [Related]
3. The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms.
Caraher EM; Gumulapurapu K; Taggart CC; Murphy P; McClean S; Callaghan M
J Antimicrob Chemother; 2007 Sep; 60(3):546-54. PubMed ID: 17595284
[TBL] [Abstract][Full Text] [Related]
4. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr).
Armstrong CM; Meyers DJ; Imlay LS; Freel Meyers C; Odom AR
Antimicrob Agents Chemother; 2015 Sep; 59(9):5511-9. PubMed ID: 26124156
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of temocillin against planktonic and sessile Burkholderia cepacia complex bacteria.
Van Acker H; Van Snick E; Nelis HJ; Coenye T
J Cyst Fibros; 2010 Dec; 9(6):450-4. PubMed ID: 20851061
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of in vitro antibacterial activity of fosmidomycin and its derivatives].
Shtannikov AV; Sergeeva EE; Biketov SF; Ostrovskiĭ DN
Antibiot Khimioter; 2007; 52(7-8):3-9. PubMed ID: 18986018
[TBL] [Abstract][Full Text] [Related]
7. Profiling of defense responses in Escherichia coli treated with fosmidomycin.
Hemmerlin A; Tritsch D; Hammann P; Rohmer M; Bach TJ
Biochimie; 2014 Apr; 99():54-62. PubMed ID: 24262605
[TBL] [Abstract][Full Text] [Related]
8. Burkholderia cepacia complex: beyond pseudomonas and acinetobacter.
Gautam V; Singhal L; Ray P
Indian J Med Microbiol; 2011; 29(1):4-12. PubMed ID: 21304187
[TBL] [Abstract][Full Text] [Related]
9. Efflux pumps may play a role in tigecycline resistance in Burkholderia species.
Rajendran R; Quinn RF; Murray C; McCulloch E; Williams C; Ramage G
Int J Antimicrob Agents; 2010 Aug; 36(2):151-4. PubMed ID: 20399621
[TBL] [Abstract][Full Text] [Related]
10. Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake.
Brown AC; Parish T
BMC Microbiol; 2008 May; 8():78. PubMed ID: 18489786
[TBL] [Abstract][Full Text] [Related]
11. Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy.
McKenney ES; Sargent M; Khan H; Uh E; Jackson ER; San Jose G; Couch RD; Dowd CS; van Hoek ML
PLoS One; 2012; 7(10):e38167. PubMed ID: 23077474
[TBL] [Abstract][Full Text] [Related]
12. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
Mahenthiralingam E; Baldwin A; Dowson CG
J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
[TBL] [Abstract][Full Text] [Related]
13. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence.
Drevinek P; Mahenthiralingam E
Clin Microbiol Infect; 2010 Jul; 16(7):821-30. PubMed ID: 20880411
[TBL] [Abstract][Full Text] [Related]
14. Copper as an antibacterial agent for human pathogenic multidrug resistant Burkholderia cepacia complex bacteria.
Ibrahim M; Wang F; Lou MM; Xie GL; Li B; Bo Z; Zhang GQ; Liu H; Wareth A
J Biosci Bioeng; 2011 Dec; 112(6):570-6. PubMed ID: 21925940
[TBL] [Abstract][Full Text] [Related]
15. Sponge-associated microbial Antarctic communities exhibiting antimicrobial activity against Burkholderia cepacia complex bacteria.
Papaleo MC; Fondi M; Maida I; Perrin E; Lo Giudice A; Michaud L; Mangano S; Bartolucci G; Romoli R; Fani R
Biotechnol Adv; 2012; 30(1):272-93. PubMed ID: 21742025
[TBL] [Abstract][Full Text] [Related]
16. Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity.
Wiesner J; Ortmann R; Jomaa H; Schlitzer M
Arch Pharm (Weinheim); 2007 Dec; 340(12):667-9. PubMed ID: 17994601
[TBL] [Abstract][Full Text] [Related]
17. A high-throughput screening assay for simultaneous selection of inhibitors of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate synthase (Dxs) or 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr).
Humnabadkar V; Jha RK; Ghatnekar N; De Sousa SM
J Biomol Screen; 2011 Mar; 16(3):303-12. PubMed ID: 21335601
[TBL] [Abstract][Full Text] [Related]
18. Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase.
Deng L; Sundriyal S; Rubio V; Shi ZZ; Song Y
J Med Chem; 2009 Nov; 52(21):6539-42. PubMed ID: 19888756
[TBL] [Abstract][Full Text] [Related]
19. α,α-Difluorophosphonohydroxamic Acid Derivatives among the Best Antibacterial Fosmidomycin Analogues.
Dreneau A; Krebs FS; Munier M; Ngov C; Tritsch D; Lièvremont D; Rohmer M; Grosdemange-Billiard C
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443699
[TBL] [Abstract][Full Text] [Related]
20. The Mla Pathway Plays an Essential Role in the Intrinsic Resistance of Burkholderia cepacia Complex Species to Antimicrobials and Host Innate Components.
Bernier SP; Son S; Surette MG
J Bacteriol; 2018 Sep; 200(18):. PubMed ID: 29986943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
